QuickAccess read/Endocrine & Metabolic/Peptide NICE Backed a Weekly Insulin Before It Has a Licence, Then Told Prescribers to Pick the Cheapest Option Athithi Verma· 25 August 2026· 2 min read· Synopulse NICE published final draft guidance recommending insulin efsitora alfa (Onswik), from Eli Lilly, for adults with type 2 diabetes. Given once weekly by pre-filled … Read more
https://synopulse.com/wp-content/uploads/2026/08/Roche-Paid-190-Million-Up-Front-on-a-2.3-Billion-Headline-for-a-Phase-1-Obesity-Asset.webp
The order moves these tests from PMA to 510(k). One special control was deleted, and the predicate chain is where the change compounds.
One drug reached review only because payers filed for a manufacturer that had not. The other was recommended on evidence the committee called inconclusive.
A biosimilar licence used to be the scarce asset. In ustekinumab it is the entry ticket, and the returns go to whoever solves supply and device.
The 22.9% figure driving coverage of European launch delays is 48 products falling to 37. The pricing finding underneath it is stronger and barely quoted.
Same drug, same week, two Asian markets. The regulator approved on progression-free survival. The payer funded only the regimen with overall survival data.
Three glioblastoma patients returned identical MGMT results and behaved differently on a barrier chip. The sample size is three, and the framing still matters.
Aletta matches human phlebotomists only when it agrees to attempt a draw. Narwhal cleared on bench and animal data, citing a trial with a different probe.
Pasatru’s flare benefit is clinician-assessed only. GENGLYCOS is indicated to reduce cornstarch intake. Two firsts, both measured a step from the patient.